Our data suggest that the supplementation of TYK2/STAT4/PIM pathway-driven small molecule inhibitors to TKI treatments could be a novel therapeutic approach to treat AML and prevent disease relapse. The gene discussed is PIM1; the disease is acute myeloid leukemia.